文献速递肿瘤 PET/CT

肺癌分期:全身PET/CT与全身体PET/CT的比较

Staging lung cancer: total-body PET/CT or whole-body PET/CT?
PubMed 文献 · EJNMMI Res · 2025-10-08

本研究纳入763例肺癌患者,评估全身体PET/CT相比传统全身PET/CT对分期的影响。全身体PET/CT在60.4%的肢体转移患者中检出额外转移,但仅1例(0.3%的IV期患者)发生分期改变,肿瘤治疗改变为0%。结论认为全身成像已能满足肺癌临床分期需求。

要点

  • 全身体PET/CT在约20%的IV期肺癌患者中检出更多远端转移。
  • 仅1例(0.3%的IV期患者)因全身体PET/CT发生分期改变。
  • 全身体PET/CT未导致肿瘤治疗改变(0%)。

核心结论

  • 全身成像足以满足肺癌的临床分期要求。
  • 全身体PET/CT虽在约20%的IV期肺癌患者中检出更多远端转移,但仅1例发生分期改变且肿瘤治疗改变为0%。

研究设计与样本

  • 研究纳入763例肺癌患者,比较全身体PET/CT与传统全身PET/CT对分期的影响。

主要发现

  • 763例患者中289例(37.9%)为IV期,其中96例(33.2%)有肢体转移。
  • 全身体PET/CT在60.4%(58/96)的肢体转移患者中检出额外转移,占所有IV期患者的20.1%(58/289),包括96处骨转移和43处肌肉转移。
  • 孤立肢体转移患者(n=31)中,全身体PET/CT在13例(41.9%)检出额外转移,仅1例(占IV期患者0.3%)分期改变。
  • 多发肢体转移患者(n=65)中,全身体PET/CT在45例(69.2%)检出额外转移,但分期均未改变。
  • 远端肢体转移与肢体外同时存在的骨转移(OR=8.288,95%CI:3.642-18.861)和肌肉转移(OR=3.911,95%CI:1.624-9.417)强烈相关(均P<0.001)。

临床怎么用

  • 肺癌分期可优先采用全身PET/CT,因其已能满足临床分期需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total Body PET/CT is increasingly used in clinical practice, but its benefits for lung cancer staging are not fully established. This study aimed to evaluate the impact of Total Body PET/CT on lung cancer staging compared to traditional Whole-Body PET/CT. RESULTS: Among the 763 patients, 289 (37.9%) had stage IV disease, with 96 (33.2%) showing limb metastases, including those in the lower limbs (legs) or also the upper limbs (arms). Compared to Whole-Body PET/CT, Total Body PET/CT detected additional metastases in 60.4% (58/96) of patients with limb metastases, representing 20.1% (58/289) of all stage IV patients. These included 96 bone and 43 muscle metastases. In patients with isolated limb metastases (n = 31), Total Body PET/CT detected additional metastases in 13 (41.9%) compared to Whole-Body PET/CT, altering tumor staging in only one patient (0.3% of stage IV patients). In those with multiple limb metastases (n = 65), Total Body PET/CT detected additional metastases in 45 (69.2%), but staging remained unchanged. Distal limb metastasis was strongly associated with concurrent bone (OR = 8.288, 95%CI: 3.642-18.861) and muscle metastases outside the limb (OR = 3.911, 95%CI: 1.624-9.417) (both P < 0.001). Additionally, Total Body PET/CT detected acute arthritis in 193 (25.3%) patients and benign lesions (e.g., varicose veins, neurogenic tumors, lipomas, fractures) in 68 (8.9%) compared to Whole-Body PET/CT. CONCLUSION: Whole-Body imaging is sufficient to meet the clinical staging requirements for lung cancer. Although Total Body PET/CT detects more distal metastases in approximately 20% of stage IV lung cancer patients, it led to stage shift in only one patient and 0% change in the oncologic treatment.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Zhang X, Xie J, Zheng Y, et al. Staging lung cancer: total-body PET/CT or whole-body PET/CT? EJNMMI Res. 2025. PMID: 41060537. doi:10.1186/s13550-025-01317-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。